Q1 EPS Estimates for Legend Biotech Reduced by William Blair

Legend Biotech Co. (NASDAQ:LEGN) – William Blair dropped their Q1 2025 earnings per share (EPS) estimates for Legend Biotech in a research report issued to clients and investors on Wednesday, March 12th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.40) for the quarter, down from their previous forecast of ($0.19). The consensus estimate for Legend Biotech’s current full-year earnings is ($1.31) per share. William Blair also issued estimates for Legend Biotech’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.85) EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.33 EPS and FY2026 earnings at $0.79 EPS.

Legend Biotech (NASDAQ:LEGN) last posted its earnings results on Tuesday, March 11th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.39) by $0.46. The firm had revenue of $186.50 million for the quarter, compared to analyst estimates of $179.00 million. Legend Biotech had a negative return on equity of 29.69% and a negative net margin of 66.92%. Legend Biotech’s revenue for the quarter was up 134.6% compared to the same quarter last year. During the same period last year, the company earned ($0.40) earnings per share.

Other equities analysts also recently issued research reports about the company. Morgan Stanley lowered their price target on Legend Biotech from $82.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday. HC Wainwright increased their price target on Legend Biotech from $73.00 to $75.00 and gave the stock a “buy” rating in a research report on Wednesday, March 12th. Piper Sandler reiterated an “overweight” rating and set a $78.00 price target on shares of Legend Biotech in a research report on Monday, December 30th. Royal Bank of Canada reiterated an “outperform” rating and set a $86.00 price target on shares of Legend Biotech in a research report on Monday, December 9th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $83.00 price target on shares of Legend Biotech in a research report on Monday, December 9th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, Legend Biotech currently has an average rating of “Moderate Buy” and a consensus target price of $79.00.

Legend Biotech Stock Down 0.2 %

Legend Biotech stock opened at $37.88 on Monday. The firm has a market cap of $6.92 billion, a price-to-earnings ratio of -39.87 and a beta of 0.19. Legend Biotech has a 52 week low of $30.17 and a 52 week high of $64.28. The business’s 50-day moving average price is $35.83 and its 200 day moving average price is $40.47. The company has a quick ratio of 4.90, a current ratio of 4.98 and a debt-to-equity ratio of 0.27.

Hedge Funds Weigh In On Legend Biotech

A number of institutional investors have recently added to or reduced their stakes in the stock. Lansforsakringar Fondforvaltning AB publ purchased a new position in Legend Biotech during the fourth quarter worth approximately $914,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Legend Biotech during the fourth quarter worth approximately $776,000. Polar Asset Management Partners Inc. lifted its position in Legend Biotech by 65.8% during the fourth quarter. Polar Asset Management Partners Inc. now owns 24,638 shares of the company’s stock worth $802,000 after buying an additional 9,779 shares in the last quarter. GF Fund Management CO. LTD. purchased a new position in Legend Biotech during the fourth quarter worth approximately $56,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Legend Biotech by 36.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 136,438 shares of the company’s stock worth $4,440,000 after buying an additional 36,181 shares in the last quarter. Hedge funds and other institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).